Related Experiment Video
Updated: Jan 28, 2026

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
The current state and future directions of RNAi-based therapeutics
Ryan L Setten1,2, John J Rossi1,2, Si-Ping Han3,4
1Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Abstract:
The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all human cells. Small double-stranded RNA molecules can efficiently trigger RNAi silencing of specific genes, but their therapeutic use has faced numerous challenges involving safety and potency. However, August 2018 marked a new era for the field, with the US Food and Drug Administration approving patisiran, the first RNAi-based drug. In this Review, we discuss key advances in the design and development of RNAi drugs leading up to this landmark achievement, the state of the current clinical pipeline and prospects for future advances, including novel RNAi pathway agents utilizing mechanisms beyond post-translational RNAi silencing.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Experimental RNAi
Cardiovascular Drugs: Classification based on Therapeutic Indications
Therapeutic Index
Electrical Current
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...

